Ethic is an investment firm founded in 2015 to help investors align their portfolios with their values while pursuing strong financial performance. For Thrivent Charitable, Ethic built a customized portfolio emphasizing companies demonstrating responsible business practices, including environmental stewardship, fair treatment of workers, and strong corporate leadership.

Ethic’s role extends beyond selecting which companies to hold. As a shareholder, Ethic votes on Thrivent Charitable’s behalf at company meetings, supporting long-term sustainability and responsible business practices. Through this approach, Ethic helps ensure investments in the Impact Fund reflect the values our donors cherish the most.

Reach Capital is a venture capital firm established in 2015 by a team of education and technology experts, investing in early-stage companies focused on learning, work, and health. The firm supports entrepreneurs developing innovative solutions to expand access to opportunity and improve quality of life. Reach combines deep industry expertise with a hands-on approach to help companies grow and scale their impact.

One example of Reach Capital’s work is their investment in Cartwheel Care, a mental health platform partnering with K–12 school districts to connect students with licensed therapists. Cartwheel Care currently serves 12 school districts across Wisconsin, bringing this support to communities in Thrivent Charitable’s own backyard. By connecting schools with access to mental health support, Cartwheel Care helps reduce common barriers to care, including long wait times, transportation, and cost. Today, the company serves school districts across the country, helping more students access the support they need to thrive.

1315 Capital invests in growth equity healthcare companies developing practical products improving patient care and healthcare delivery. The fund focuses on businesses with proven solutions addressing real-world needs across pharmaceutical products and outsourcing, medtech, and health and wellness. By backing companies with established traction, 1315 Capital supports innovation able to scale and deliver meaningful benefits to patients, providers and healthcare systems while pursuing strong financial returns.

A clear example of 1315 Capital’s impact is its investment in Nu-Tek Biosciences, which uses technology, helping make drug development more sustainable and efficient. Another portfolio company, Biocoat, develops specialized coatings for medical devices that reduce friction and improve performance in tools such as catheters and guidewires. Together, these investments demonstrate how 1315 supports healthcare solutions that enhance safety, efficiency and outcomes in everyday clinical settings.